{"name":"Calliditas Therapeutics AB","slug":"calliditas-therapeutics-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"TARPEYO®","genericName":"TARPEYO®","slug":"tarpeyo","indication":"Other","status":"marketed"},{"name":"NEFECON","genericName":"NEFECON","slug":"nefecon","indication":"IgA nephropathy with risk of progression to end-stage renal disease","status":"phase_3"},{"name":"Xepol","genericName":"Xepol","slug":"xepol","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TARPEYO®","genericName":"TARPEYO®","slug":"tarpeyo","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NEFECON","genericName":"NEFECON","slug":"nefecon","phase":"phase_3","mechanism":"Nefecon is a targeted immunosuppressant that delivers budesonide directly to the kidney to reduce inflammation in IgA nephropathy.","indications":["IgA nephropathy with risk of progression to end-stage renal disease"],"catalyst":""},{"name":"Xepol","genericName":"Xepol","slug":"xepol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPdnM4bkZEZlAwM3E0X2lCZ3o4VkZNeXR2RlBDNHd6enZfWTM4SmxrbDdqNWlJT3JYV0E4MU12ZjhuNTdzTE1xczRaY1RqN000b2VDREpiYTRKb1dGN3Z0YkFCQTV6Yk9aYk1FTlI3NXhwUTUxR28ySGRTX2kzc2p2VXRGR21uMjNDdVBPT0FuM2JyYW1mVFh4Yk9IMkJSQ3BTY3EzMzQwME5TaGVvUHZwcW8yUy1GU3pTaDBRT0xoNHhIbk5MNGlpZ29XcWM5d2JJaTR2MVlUaW13Y1FDSmdZVFRfZGsyX2M?oc=5","date":"2026-03-01","type":"pipeline","source":"Citeline News & Insights","summary":"Asahi Kasei Grows Pharma Business Via M&A With Niche-Focused Strategy - Citeline News & Insights","headline":"Asahi Kasei Grows Pharma Business Via M&A With Niche-Focused Strategy - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxQaVVUYU0wZkpJVncwMHNTNmFiRVJvRmdkdU1qRG1uWUJsZGZ1T21RZEF1ekUwVmF1UGpGQVhvdHB5OWR3aC02RHZwcGFnVU8wZVU3SEpFYXM4U0Utdk4zczJ3NVRudHR0Y0ZVb3pEMzBVNjVwOE1ZUDdSZnhoZExaZjRrZXJ4OWJJQVRHTE1takVES3JJdy1WUjZUQW5sZW5LSGRQdzZ2OW1qc0lVMmM1VkhJVXdSQjBoNzMzT09ybF9iRmg4MEVlRmhnanYySzlRcmtnLVhhT0duNG9odktYbWhlX2l6TzE0bjJ1SWtWT1Y4a0JxV1RfUXlLOUNSWmFOQ3RGWFZ5cGI4UHFESlQtN0gtVG1tTkF6TkRZ?oc=5","date":"2026-02-18","type":"trial","source":"Business Wire","summary":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases - Business Wire","headline":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ReEcxbU1IdXB1aUtIQ2l4dEh0YTJ6V3hDZ0pYbS1ZQ2FTUWJKNF9PaEZFTWc2SFNneFBvcHlBcG5EZFM4bm9MVzUxT0g2b1FZeGZV?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"CALT Stock Price, News & Analysis - Stock Titan","headline":"CALT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNalFYUG9lbzNXTGhhd3hPb1R4WEpoY2lIaXNqenphbGNGRlY4cy1pYnhUMFlWWUJUdjhNUHJTdVhaRXFoLThUZlJxR3Jxb3RkX3FmQS1VT2h3dVo1OFdWQ0ZUN3FTWFpBRl9tcWFKMlFCbXMxYUtuemNvbDluZXJRZnlrckw5QlcwNGtja3pZWi1hbC1fUC1BMlByMnA2d0JRQVNqaVVXRmZaTmppZzRZbDVn?oc=5","date":"2025-04-16","type":"trial","source":"Uppsala universitet","summary":"Welcome Calliditas Therapeutics • New Industrial partner in SweDeliver - Uppsala universitet","headline":"Welcome Calliditas Therapeutics • New Industrial partner in SweDeliver","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOTEhxYU5QUWFtRDVFRHJJWDdzd1hxenB6aDE1eWtqbE1EaHdYUmNuN0hDWEJ5aEx5eE1rcklyN1VqNXVpZk9TTUJKVEhCTzJ1XzR3ZHhxOEw5NzllTkloNzVnMkNncWMyVjB6U25sTzF1MXVBRHhPbjYyRUt3R3FNNGsxVThmVksxWk11cEFWcE9rZVdidUd5aUUtektsSURTcHNGVXFNRlFrSWFTMGozZVVGWGZYa1J6allHYnJ2TnJRQnhFdkE?oc=5","date":"2024-09-05","type":"pipeline","source":"European Pharmaceutical Review","summary":"Advancing NOX inhibitors for treating fibrotic diseases and cancer - European Pharmaceutical Review","headline":"Advancing NOX inhibitors for treating fibrotic diseases and cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNdlljVjlBWmlJbzBjaDBGaG9nYUxXRTAtUzVkcENLWlAyY0llWjBzRUZMSkd3MmlmYmJ1TGRhakhoU2QxQmxqVllwSk9qRmNmOUF5eGRGa1FpWlB0N1VrRkZtTFhYOWlORllPaDhLeHZ2NlBZZ0E2Z2J4UjJiYnFuMkJ1SjJlTW1zeUwzMGIySUhwcUd5cWQtZXQyUQ?oc=5","date":"2024-05-28","type":"deal","source":"Contract Pharma","summary":"Asahi Kasei to Acquire Calliditas Therapeutics AB - Contract Pharma","headline":"Asahi Kasei to Acquire Calliditas Therapeutics AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQd1U3YXpqQW1sOU9jTmF4VmRDSGhFbVI0dlBoa1gwdVJzTFpweUs3NjMyRnJCX1pmU053VmktU0llbDZPMDgtMk1aXzBnbHlvdWRjbXJtYTd6aU5kazRQLTN1bXRXQ2ZvNXRrbnQtWnpsNHJFc2s4d1VhbjFlSVRjS1NxeVJiNFQ0U2cxdTJ2RGxCenhROW41dnhqaTlsUlh2U1dVaVRFd0NZMGtoYmhOX2U4RUJLSnNXbmFUdk15NkhrU1dWclVLZjkxM3IzMi1ualdEUlpLdDFSSXNCaEF1YmFHNUJaNENmTU1sbjh0TQ?oc=5","date":"2024-05-28","type":"deal","source":"Business Wire","summary":"Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company - Business Wire","headline":"Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRk9SQ3RBVjBIQmVTUDZxY0RLQUFyYVNDdmxWLU1BMEY5VXktcUExc09FVTZ2SnUzR043VHhwdDF6OEphM2xwdGlFbm10M1g5MzJmSlhJTkxLTW5NLXJiU0tCdGJVcFBEMURKZTJlcF9rY3JVQjBGS1JrRG4wMGNROGNNLVczbHNqdVNfOXd5RXBMQQ?oc=5","date":"2024-05-28","type":"deal","source":"Fierce Pharma","summary":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas - Fierce Pharma","headline":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQWTVJZXdjaE9Jb2VWN0NKZmctWEQ1bEFxemphMXhwaW54c1Axc2s1WC14dzVXMTNyX3BMUThrXzQycWtUc0JMNXE0dVRsVTZiVkt4N2JFR2haMjMxWGNSZDFWcTNDa19OMXFZYm1ESTN4dFFScDR5dXdDR3dqMVVvMmpEWTVad3BnRFg3OUR2UUNNVWx1TE1XSmRtb3l2NVY4VHF6Z2ZjVE5ESHg4LVlmRA?oc=5","date":"2024-05-28","type":"deal","source":"Citeline News & Insights","summary":"Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy - Citeline News & Insights","headline":"Asahi Kasei Furthers Its US, Health Care Growth With $1.1bn Calliditas Buy - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMmFKQ2Iwa0FJSy1vc0ltdXIyX0RyZEU4SkVSV2xXdjBnR2NZak5SNUhCanRDbmdnRzNEOUNpa0JST0hBMGY3T00xTURzd3kyUHJuTjNZemx2QTk0YzhSX0dtWDd1bEZUZ1Z3RGVYLThsRkxNd29iOWFvMkJaaDVndjlDTG5CdkM1S2dHY2gxNy1ZTGpTcGdtb1hYNWlNb0VHanN3SFFYRzE?oc=5","date":"2024-05-28","type":"deal","source":"reuters.com","summary":"Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion - reuters.com","headline":"Asahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQRkhySVNIdW5OSUk4MDJCOFM2VWxEUnJNYURyb1NXUjk2cl9HeFlYWEZKY0RXY0h5V0txT3dRSy1XQXBZRERtVlNhMU9IOGYzQ3hRdjRhaG90eFJlemFFeDV1ZW00dm1PMU9kRGZlZ1Y0d3d6c3g2UlpZWVVLMzdkNjU2b1pWZUJmTTAzZjRZcm4zZDV5dFZGcE1tdFF2WDR1M0VnNlRHdTJDaG1nRmZOQ2JkNmRqSGx6dW1XbS1mV1hIdm5VcGxxUUlQcw?oc=5","date":"2023-12-21","type":"regulatory","source":"reuters.com","summary":"US FDA approves Sweden-based Calliditas' kidney disease drug - reuters.com","headline":"US FDA approves Sweden-based Calliditas' kidney disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPV1FTTW1Rd0F5TjVwZG5VazdSeEpaeTdwZ0R3bERjZzZabUU2TjlLS3ZfTlJtVW1hNlRXREpJV19HNU5zbHhRUWdWdGhScTJHejFrd2ZrNXhBMi1kR2IycHJNM3ZzSU4tNlBzQmlIbGRRa0NJSU9FaDlHMV94bjVMWFRyd0tpUXRSTDBIN0lnRjR3WEVTNTVhdks2RXlEaDVYODRHSVJ2Tk1FSXZrN0h6aGdsTFF6YmlUVXBfRlUyU3JYa0NpN2ZJYg?oc=5","date":"2023-02-17","type":"regulatory","source":"reuters.com","summary":"U.S. FDA approves Travere Therapeutics kidney disorder drug - reuters.com","headline":"U.S. FDA approves Travere Therapeutics kidney disorder drug","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":1,"phase_3":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}